ARA-290 vs TB-500 | Research Comparison | QSC Peptides
ARA-290 vs TB-500: Research Comparison
Mechanism, research applications, and key differences
Quick Comparison
Factor
ARA-290
TB-500
Primary Target
Innate Repair Receptor (IRR)
See TB-500 hub
Origin
EPO helix B surface peptide
Distinct origin
Key Research
Phase 2: small fibre neuropathy, metabolic repair
See TB-500 hub
Detailed Comparison
ARA-290 activates IRR-mediated cytoprotection; TB-500 (Thymosin Beta-4) promotes actin polymerisation and angiogenesis. Different repair mechanisms — TB-500 is stronger for structural tissue repair, ARA-290 for neuropathic and metabolic cytoprotection.
Which to Choose for Your Research?
The choice depends on your primary research target. ARA-290 is the right tool when the research question involves IRR-mediated cytoprotection — neuropathy models, sarcoidosis inflammation, or metabolic beta cell protection. TB-500 suits different primary targets. For comprehensive cytoprotection research, some protocols combine both compounds targeting complementary pathways.
